On March 15, 2023 Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, reported its financial results and provide a corporate update for the fiscal year ended December 31, 2022 on Wednesday, March 29, 2023 (Press release, MediGene, MAR 15, 2023, View Source [SID1234628834]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Following the release of the full year 2022 financial results on Medigene’s website, the company will host a conference call that same day at 3 p.m. CET (9 a.m. ET).

Full details for the conference call and webcast are as follows:

Date March 29, 2023
Time 3:00 p.m. CET (9 a.m. ET)
U.S. Dial-in Number: +1 877-451-6152
Int’l Dial-in Number: +1 201-389-0879
Conference ID: 13736670
Webcast: Join the live webcast here or at View Source
Please dial in 10 minutes ahead of time to ensure a timely start of the conference call.

Following the call, an archived webcast will be accessible on the Investors & Media section of the Medigene website: View Source